U.S. markets closed

Galmed Pharmaceuticals Ltd. (GLMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.6100-0.1400 (-5.09%)
At close: 4:00PM EDT
Sign in to post a message.
  • B
    Brent
    Following the earnings, H.C. Wainwright analyst Ed Arce reiterated a Buy and a price target of $25 (812.4% upside potential) on the stock.
  • E
    Exaar
    It doesn't take long for investors to discover this company. Read their report, they have a great drug. about 400 patient were tried and FDA t. fast priority was defined.
    Bullish
  • m
    miki
    Its coming 🚀🚀🚀🚀🚀
  • E
    Exaar
    Someone is collecting this stock. It increases the share ratio by spreading it over time. This is too underrated. It is an incredible development, if anyone is reading this data that has been tried in the last stage and in 400 patients.
    Bullish
  • C
    CNBC Juice
    So many great things in the works. This could easily hit 15 bucks shortly.
  • E
    Exaar
    The market for the drugs they are working on and approaching phase 3 is incredibly large. this must have been more valuable than the diamond. 3 percent of the American population. Think about it. It's too cheap for such a drug.
  • m
    miki
    I live this Stock 😍😍😍this Going to 20 Dollar
  • J
    Jane
    Ibex Investors, LLC, is noted in Holders above to have 1,525,000 shares of Galmed in their portfolio.
    They have an interesting website. Look under their "Segmented" strategies to understand their
    method of operation. You may find it interesting.
  • m
    miki
    Go 🎉🎉🎉🎉🚀🚀🚀🚀🚀🚀
  • C
    CNBC Juice
    Popped up 5% after hours…something might be brewing
  • i
    itssofine2
    I've been watching this jump for the last several trading days & had to take a sizable long position.....
    We will see what happens
  • L
    LGALS3
    Also take a look at GALT, it's the next one to run up.
    Here is the latest map of the competitive landscape.
    https://charts.stocktwits.com/production/original_339538530.png
  • E
    Exaar
    #AMC #SNDL #NCTY #BB

    The price target for 5 analysts is 16-21. There is currently a price at Institutions 3.22. It's so underrated. Very cheap.
    Bullish
  • d
    dc
    interesting chart, looks like mini cup with handle forming now
  • E
    Exaar
    No volume other than the exchange of funds from the XBI etf. PR needs to be released before this thing turns into a dying horse. Have you had an FDA meeting? are there any deals????
  • E
    Exaar
    For a stock with 2.34 cash per share, it makes the market value of the cash on hand. Although it does not produce anything, it cannot go below this value, but it has even decreased below 2.34. Open it and look at the chart.
    This company is a very cheap company that develops drugs that produce solutions for fatty liver and is about to publish Phase 3 studies, which are at the stage of agreement. It will not take long to reach its real price as it has been ignored.
  • E
    Exaar
    Aramchol

    Galmed stated in the company’s Q1 earnings release that the histology (microscopic study of tissues and cells) results from around 33.3% of the study population will likely be available in the fourth quarter of this year. This 33.3% of the study population accounts for around 50 subjects who had higher exposure to Aramchol and are part of the open-label section of the ARMOR Phase 3 study.
    Bullish
  • A
    ANDRE
    162 / 5000
    Vertaalresultaten
    VOLUME IS STILL VERY LOW, THEREFORE BUY ANY 10000 TO 30000, THIS COMPANY HAS A GREAT FUTURE. NORMALLY THIS IS A SHARE THAT SHOULD BE OVER 15 DOLLARS.
  • A
    ANDRE
    REMEMBER THE BIG BUYERS COMING, INSTITUTES ETC, NOW IT'S A BARGAIN, I'M GOING TO BUY ANOTHER 3000 AS SOON AS POSSIBLE.